Information Provided By: 
Fly News Breaks for March 7, 2017
NVO
Mar 7, 2017 | 12:56 EDT
Barclays analyst Emmanuel Papadakis reinstated Novo Nordisk with an Underweight rating and DKK 210 price target. The analyst believes the valuation premium to the group is unwarranted and feels the company's 2017 guidance "does not look cautious."
News For NVO From the Last 2 Days
NVO
Apr 24, 2024 | 15:59 EDT
Senator Bernie Sanders is set to lead a Senate investigation into the high prices charged by Novo Nordisk for its diabetes and anti-obesity medications Ozempic and Wegovy, The Financial Times' Oliver Barnes reports. Sanders wrote to Novo Nordisk CEO Lars Fruergaard Jorgensen to inform him the U.S. committee that oversees healthcare is probing "the outrageously high prices" the company charges for the drugs, saying that the drugs "will not do any good for the millions of patients who cannot afford them." Reference Link
